Adagio Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
The filing reports results of Adagio Therapeutics, Inc.’s Annual Meeting of Stockholders held on June 22, 2022. The company’s common stock traded on Nasdaq under the symbol ADGI. The provided filing identifies the registrant as Adagio Therapeutics, Inc.; it does not address the company’s subsequent name change to Invivyd, Inc.
Financial and Operating Metrics
This Form 8-K does not report revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or financial guidance. The filing text does not provide clear values for these metrics.
Material Changes and Meeting Results
- Stockholders elected Tamsin Berry, Marc Elia, and Clive Meanwell as Class I directors, each for a three-year term expiring at the 2025 annual meeting.
- Votes in favor were 79,059,858 for Ms. Berry, 79,080,114 for Mr. Elia, and 79,060,114 for Dr. Meanwell; withheld votes were 8,385,835, 8,365,579, and 8,385,579, respectively.
- Stockholders approved a non-binding advisory proposal recommending that the Board be declassified in advance of the 2023 annual meeting. The vote was 82,839,503 for, 30,230 against, and 4,575,960 abstentions.
Governance, Compensation, and Other Matters
- Each newly elected non-employee director will receive compensation under the company’s director compensation program, including a one-time nonqualified stock option to purchase 150,000 shares at $3.09 per share, equal to the common stock closing price on June 22, 2022.
- The directors will enter into the company’s standard indemnification agreements, which may require indemnification for specified expenses, judgments, fines, and settlement amounts arising from their service.
- The filing discloses no arrangements or understandings relating to the directors’ election and no related-party transactions requiring disclosure under Item 404(a).
Investor Verification Items
- Verify implementation of the advisory declassification proposal and any resulting amendments to the company’s governing documents.
- Confirm the terms, vesting conditions, and accounting impact of the 150,000-share option grants to each director.
- Review subsequent filings for any changes in board composition, director compensation, company name, ticker symbol, or capital structure.
- Consult the company’s periodic financial filings for revenue, cash usage, liquidity, debt, and operating-risk information, none of which is included in this Form 8-K.